ImageneBio, Inc. (IMA) Fair Value 2026

IMA · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.7 /10

32 fundamental signals · 0 models active

Value Trap Risk

DANGER (63/100)

Quick Summary — As of 2026-08-27, ImageneBio, Inc. (IMA) trades at $5.33. QOC: 5.7/10. Value Trap Risk: 63/100 (DANGER). 0/13 models active.

Key Facts

Ticker
IMA
Price
$5.33
Quality Score
5.7/10
Value Trap Risk
63/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 63 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give IMA?

0 Intrinsic Value Models vs. Current Price ($5.33)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is ImageneBio, Inc. (IMA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ImageneBio, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About IMA?

0 of 13 models are currently active for IMA. See which stocks rank higher →

How Does IMA Rank in Biotechnology?

Among 620 Biotechnology stocks, IMA ranks #192 by Quality of Company score. CirclFi's QOC score of 5.7/10 evaluates 32 fundamental signals. A score of 5.7 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, ImageneBio, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating IMA should weigh these sector-specific dynamics alongside our model-derived fair values.

Is IMA a Value Trap?

CirclFi's Value Trap algorithm assigns IMA a score of 63/100 (DANGER). This is a high-risk signal. Deteriorating fundamentals suggest the discount may be justified. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for ImageneBio, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, ImageneBio, Inc. is rated at 5.7/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement. Notably, value trap risk is elevated.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every IMA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ImageneBio, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

CGONCG Oncology, Inc.QOC 5.7WHWKWhitehawk Therapeutics, Inc.QOC 5.7FTREFortrea Holdings Inc.QOC 5.7OVIDOvid Therapeutics Inc.QOC 5.7AAPGAscentage Pharma Group InternatQOC 5.7IVAInventiva S.A.QOC 5.7FBLGFibroBiologics, Inc.QOC 4.9BBLGBone Biologics CorporationQOC 4.2SPROSpero Therapeutics, Inc.QOC 7.4EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: CGON · WHWK · FTRE · OVID · AAPG · IVA · FBLG · BBLG · SPRO · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to IMA?

6 companies across all industries closest to IMA’s Quality of Company score of 5.7/10.

CETXCemtrex, Inc.QOC 5.7CMTLComtech Telecommunications Corp.QOC 5.7TLPHTalphera, Inc.QOC 5.7RWTRedwood Trust, Inc.QOC 5.7SAIHSAIHEAT LimitedQOC 5.7NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CETX · CMTL · TLPH · RWT · SAIH · NVDA

Where Does IMA Sit in CirclFi's Biotechnology Rankings?

IMA is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About ImageneBio, Inc.’s Valuation?

What is ImageneBio, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ImageneBio, Inc. (IMA). The Quality of Company score is 5.7/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is IMA overvalued or undervalued right now?

At $5.33, 0 of 0 active models suggest IMA may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits ImageneBio, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 5.7 mean for IMA?

ImageneBio, Inc.'s QOC of 5.7/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on IMA?

CirclFi analyzes IMA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is IMA a value trap in 2026?

ImageneBio, Inc.'s Value Trap score is 63/100 (DANGER). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ImageneBio, Inc. (IMA) a Quality of Company score of 5.7/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/IMA/ · Methodology
Primary sources for this IMA valuation
  • Financial statements: ImageneBio, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001835579) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for IMA as of ; valuations recomputed .